nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-1040Research ArticleВСЕМИРНЫЙ ДЕНЬ ПОЧКИWORLD KIDNEY DAYДиабетическая почка: действуй сейчас или заплатишь потомDiabetic kidney disease: Act now or pay laterАткинсРоберт С.AtkinsRobert C.noemail@neicon.ruЦимметПаульZimmetPaulnoemail@neicon.ru200919062025114272274Copyright © Аткинс Р.С., Циммет П., 20252025Аткинс Р.С., Циммет П.Atkins R.C., Zimmet P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/1040

По поручению Комитета по проведению Всемирного Дня Почки – 2010 Международного Общества Нефрологов/Международной Федерации Почечных Фондов и Международной Федерации Диабета Всемирный День Почки 11 марта 2010 г.: диабетическая почка – мы должны действовать Перевод с английского Е.В. Захаровой. Одобрен авторами и Комитетом по проведению Всемирного Дня Почки, представляющим Международное Общество Нефрологов и Международную Федерацию Почечных Фондов.

For the 2010 International Society of Nephrology/International Federation of Kidney Foundations World Kidney Day Steering Committee (RA) and the International Diabetes Federation (PZ) World Kidney Day 11 March 2010: we must act on diabetic kidney disease

ReferencesInternational Diabetes Federation and International Society of Nephrology, Diabetes and kidney disease: time to act. 2003: Brussels.International Diabetes Federation and International Society of Nephrology, Diabetes and kidney disease: time to act. 2003: Brussels.Zimmet P., Alberti K., Shaw J. Global and societal implications of the diabetes epidemic // Nature. 2001. Vol. 414. P. 782–787.Zimmet P., Alberti K., Shaw J. Global and societal implications of the diabetes epidemic // Nature. 2001. Vol. 414. P. 782–787.King H., Aubert R., Herman W. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections // Diabetes Care. 1998. Vol. 21. P. 1414–1431.King H., Aubert R., Herman W. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections // Diabetes Care. 1998. Vol. 21. P. 1414–1431.Yoon K. et al. Epidemic obesity and type 2 diabetes in Asia // Lancet. 2006. Vol. 368. P. 1681–1688.Yoon K. et al. Epidemic obesity and type 2 diabetes in Asia // Lancet. 2006. Vol. 368. P. 1681–1688.Sicree R., Shaw J., Zimmet P. Diabetes and impaired glucose tolerance // Diabetes Atlas. 3rd edition. Gan D., Editor. International Diabetes Federation: Brussels, 2006. P. 15–109.Sicree R., Shaw J., Zimmet P. Diabetes and impaired glucose tolerance // Diabetes Atlas. 3rd edition. Gan D., Editor. International Diabetes Federation: Brussels, 2006. P. 15–109.Reutens A.T., Prentice L., Atkins R. The Epidemiology of Diabetic Kidney Disease // The Epidemiology of Diabetes Mellitus. 2nd Edition. Ekoé J. et al. Editors. 2008, John Wiley & Sons Ltd: Chichester.499–518.Reutens A.T., Prentice L., Atkins R. The Epidemiology of Diabetic Kidney Disease // The Epidemiology of Diabetes Mellitus. 2nd Edition. Ekoé J. et al. Editors. 2008, John Wiley & Sons Ltd: Chichester.499–518.National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. International comparisons, in 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2007, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda. P. 239–254.National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. International comparisons, in 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2007, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda. P. 239–254.Appendix II, in ANZDATA Registry Report 2008. McDonald S., Excell L., Livingston B., Editors. 2008, Australia and New Zealand Dialysis and Transplant Registry: Adelaide. P. 1–97.Appendix II, in ANZDATA Registry Report 2008. McDonald S., Excell L., Livingston B., Editors. 2008, Australia and New Zealand Dialysis and Transplant Registry: Adelaide. P. 1–97.Yamagata K. et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening // Clin Exp Nephrol. 2008. Vol. 12. P. 1–8.Yamagata K. et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening // Clin Exp Nephrol. 2008. Vol. 12. P. 1–8.Lysaght M. Maintenance dialysis population dynamics: Current trends and long term implications // J Am Soc Nephrol. 2002. Vol. 13. P. S37–40.Lysaght M. Maintenance dialysis population dynamics: Current trends and long term implications // J Am Soc Nephrol. 2002. Vol. 13. P. S37–40.Adler A. et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) // Kidney Int. 2003. Vol. 63. P. 225–232.Adler A. et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) // Kidney Int. 2003. Vol. 63. P. 225–232.Retnakaran R. et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74 // Diabetes. 2006. Vol. 55 (6). P. 1832–1839.Retnakaran R. et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74 // Diabetes. 2006. Vol. 55 (6). P. 1832–1839.Parving H. et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective // Kidney Int. 2006. Vol. 69 (11). P. 2057–2063.Parving H. et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective // Kidney Int. 2006. Vol. 69 (11). P. 2057–2063.Ninomiya T. et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes // J Am Soc Nephrol. 2009. Vol. 20 (8). P. 1813–1821.Ninomiya T. et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes // J Am Soc Nephrol. 2009. Vol. 20 (8). P. 1813–1821.Dunstan D. et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study // Diabetes Care. 2002. Vol. 25 (5). P. 829–834.Dunstan D. et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study // Diabetes Care. 2002. Vol. 25 (5). P. 829–834.White S. et al. Limited knowledge of kidney disease in a survey of AusDiab study participants // Med J Aust. 2008. Vol. 188 (4). P. 204–208.White S. et al. Limited knowledge of kidney disease in a survey of AusDiab study participants // Med J Aust. 2008. Vol. 188 (4). P. 204–208.Whaley-Connell A. et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) // Am J Kidney Dis. 2009. Vol. 53 (Suppl. 4). P. S11–21.Whaley-Connell A. et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) // Am J Kidney Dis. 2009. Vol. 53 (Suppl. 4). P. S11–21.Thomas M., Viberti G., Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point? // Nat Clin Pract Nephrol. 2008. Vol. 4 (1). P. 2–3.Thomas M., Viberti G., Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point? // Nat Clin Pract Nephrol. 2008. Vol. 4 (1). P. 2–3.Holman R. et al. 10-year follow-up of intensive glucose control in type 2 diabetes // N Engl J Med. 2008. Vol. 359 (15). P. 1577–1589.Holman R. et al. 10-year follow-up of intensive glucose control in type 2 diabetes // N Engl J Med. 2008. Vol. 359 (15). P. 1577–1589.Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? // Diabet Med. 2008. Vol. 25 (Suppl. 2). P. 25–29.Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? // Diabet Med. 2008. Vol. 25 (Suppl. 2). P. 25–29.Gaede P. et al. Effect of a multifactorial intervention on mortality in type 2 diabetes // N Engl J Med. 2008. Vol. 358 (6). P. 580–591.Gaede P. et al. Effect of a multifactorial intervention on mortality in type 2 diabetes // N Engl J Med. 2008. Vol. 358 (6). P. 580–591.Patel A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial // Lancet. 2007. Vol. 370. P. 829–840.Patel A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial // Lancet. 2007. Vol. 370. P. 829–840.Group A.C. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N Engl J Med. 2008. Vol. 358. P. 2560–2572.Group A.C. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N Engl J Med. 2008. Vol. 358. P. 2560–2572.Zoungas S. et al. The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE // Diabetes Care. 2009. Aug 3 [Epub ahead of print].Zoungas S. et al. The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE // Diabetes Care. 2009. Aug 3 [Epub ahead of print].Ruggenenti P. et al. Preventing microalbuminuria in type 2 diabetes // N Engl J Med. 2004. Vol. 351 (19). P. 1941–1951.Ruggenenti P. et al. Preventing microalbuminuria in type 2 diabetes // N Engl J Med. 2004. Vol. 351 (19). P. 1941–1951.Parving H. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // N Engl J Med. 2001. Vol. 345 (12). P. 870–878.Parving H. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // N Engl J Med. 2001. Vol. 345 (12). P. 870–878.Lewis E. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N Eng J Med. 2001. Vol. 345. P. 851–860.Lewis E. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N Eng J Med. 2001. Vol. 345. P. 851–860.Burney B., Kalaitzidis R., Bakris G. Novel therapies of diabetic nephropathy // Curr Opin Nephrol Hypertens. 2009. Vol. 18 (2).107–111.Burney B., Kalaitzidis R., Bakris G. Novel therapies of diabetic nephropathy // Curr Opin Nephrol Hypertens. 2009. Vol. 18 (2).107–111.

The authors declare that there are no conflicts of interest present.